Kymera Therapeutics, Inc. Common Stock KYMR
HEALTHCARE · BIOTECHNOLOGYi
Market dataready · fetched 2026-11-11T14:54:35.230Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-11T14:54:33.322557639Z
FundamentalsAlpha Vantage · ready · quarter 2026-09-30 · fetched 2026-11-11T14:54:34.584100+00:00
Kymera Therapeutics, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 163.94 | 119.3% | 21.5% | 116.52 | 142.1% | 17.8% |
| 25Δ | 159.10 | 121.9% | 18.6% | 121.63 | 134.3% | 14.8% |
| 30Δ | 153.32 | 114.3% | 14.9% | 126.12 | 125.3% | 12.2% |
| 35Δ | 149.04 | 110.8% | 12.4% | 130.13 | 114.6% | 9.8% |
| 40Δ | 145.45 | 108.9% | 10.5% | 133.26 | 108.7% | 8.2% |
| 45Δ | 142.25 | 107.4% | 9.0% | 136.25 | 104.9% | 6.8% |
| 50Δ | 139.17 | 107.4% | 7.6% | 139.06 | 103.7% | 5.8% |
| 55Δ | 136.27 | 111.1% | 6.7% | 142.13 | 105.3% | 5.0% |
| 60Δ | 133.14 | 116.2% | 5.9% | 145.36 | 108.0% | 4.3% |
| 65Δ | 129.81 | 122.1% | 5.1% | 148.72 | 108.3% | 3.6% |
| 70Δ | 126.09 | 126.1% | 4.3% | 152.59 | 109.9% | 2.9% |
| 75Δ | 121.42 | 136.6% | 3.7% | 157.72 | 115.2% | 2.4% |
| 80Δ | 116.16 | 145.5% | 2.9% | 162.97 | 116.9% | 1.8% |
20Δ
- Pseudo strike
- 163.94
- IV
- 119.3%
- B/E move
- 21.5%
- Pseudo strike
- 116.52
- IV
- 142.1%
- B/E move
- 17.8%
25Δ
- Pseudo strike
- 159.10
- IV
- 121.9%
- B/E move
- 18.6%
- Pseudo strike
- 121.63
- IV
- 134.3%
- B/E move
- 14.8%
30Δ
- Pseudo strike
- 153.32
- IV
- 114.3%
- B/E move
- 14.9%
- Pseudo strike
- 126.12
- IV
- 125.3%
- B/E move
- 12.2%
35Δ
- Pseudo strike
- 149.04
- IV
- 110.8%
- B/E move
- 12.4%
- Pseudo strike
- 130.13
- IV
- 114.6%
- B/E move
- 9.8%
40Δ
- Pseudo strike
- 145.45
- IV
- 108.9%
- B/E move
- 10.5%
- Pseudo strike
- 133.26
- IV
- 108.7%
- B/E move
- 8.2%
45Δ
- Pseudo strike
- 142.25
- IV
- 107.4%
- B/E move
- 9.0%
- Pseudo strike
- 136.25
- IV
- 104.9%
- B/E move
- 6.8%
50Δ
- Pseudo strike
- 139.17
- IV
- 107.4%
- B/E move
- 7.6%
- Pseudo strike
- 139.06
- IV
- 103.7%
- B/E move
- 5.8%
55Δ
- Pseudo strike
- 136.27
- IV
- 111.1%
- B/E move
- 6.7%
- Pseudo strike
- 142.13
- IV
- 105.3%
- B/E move
- 5.0%
60Δ
- Pseudo strike
- 133.14
- IV
- 116.2%
- B/E move
- 5.9%
- Pseudo strike
- 145.36
- IV
- 108.0%
- B/E move
- 4.3%
65Δ
- Pseudo strike
- 129.81
- IV
- 122.1%
- B/E move
- 5.1%
- Pseudo strike
- 148.72
- IV
- 108.3%
- B/E move
- 3.6%
70Δ
- Pseudo strike
- 126.09
- IV
- 126.1%
- B/E move
- 4.3%
- Pseudo strike
- 152.59
- IV
- 109.9%
- B/E move
- 2.9%
75Δ
- Pseudo strike
- 121.42
- IV
- 136.6%
- B/E move
- 3.7%
- Pseudo strike
- 157.72
- IV
- 115.2%
- B/E move
- 2.4%
80Δ
- Pseudo strike
- 116.16
- IV
- 145.5%
- B/E move
- 2.9%
- Pseudo strike
- 162.97
- IV
- 116.9%
- B/E move
- 1.8%
Options history
Table
| Date | IV (%) |
|---|---|
| 65.42% | |
| 66.13% | |
| 69.08% | |
| 68.68% | |
| 72.12% | |
| 61.83% | |
| 66.95% | |
| 67.45% | |
| 66.75% | |
| 67.31% | |
| 67.54% | |
| 68.52% | |
| 68.98% | |
| 68.75% | |
| 69.66% | |
| 68.56% | |
| 69.49% | |
| 72.26% | |
| 72.97% | |
| 73.52% | |
| 72.13% | |
| 76.43% | |
| 77.80% | |
| 80.99% | |
| 88.66% | |
| 89.48% | |
| 90.96% | |
| 90.89% | |
| 91.62% | |
| 91.48% | |
| 91.93% | |
| 93.94% | |
| 94.96% | |
| 95.64% | |
| 97.93% | |
| 98.60% | |
| 103.13% | |
| 104.90% | |
| 104.28% | |
| 104.32% | |
| 106.42% | |
| 110.46% | |
| 114.85% | |
| 118.74% | |
| 124.04% | |
| 129.20% | |
| 130.46% | |
| 128.70% | |
| 129.53% | |
| 130.82% | |
| 130.93% | |
| 133.80% | |
| 129.67% | |
| 128.34% | |
| 122.20% | |
| 122.23% |
Biotechnology
KYTX
Kyverna Therapeutics, Inc. is an innovative biotechnology company focused on advancing immunotherapies for autoimmune diseases and other significant health challenges. Employing…
More →KZIA
Kazia Therapeutics Limited, a biotechnology company focused on oncology, develops anticancer drugs. The company is headquartered in Sydney, Australia.
More →LBRX
LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases.…
More →LCTX
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing therapeutics for the treatment of degenerative diseases in the…
More →LEGN
Legend Biotech Corporation, a clinical-stage biopharmaceutical company, is dedicated to the discovery and development of new cell therapies for oncology and other indications in…
More →LENZ
LENZ Therapeutics Inc is a cutting-edge biopharmaceutical company dedicated to developing transformative therapies for neurological disorders, specifically targeting critical…
More →